ArticleLeukemia2025

Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.

Tim R Mocking et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.